ColBar LifeScience Ltd. (now a Johnson & Johnson company)

www.colbar.com

High-Tech Company

Acquired by Johnson & Johnson Inc.

TECH VERTICALS

Biotechnology, Life Sciences, MedTech, Therapeutics

General Data

Sector	Biomed
Company Stage:	Initial Revenues
Established	1995
Number of Employees	60

DESCRIPTION

ColBar develops, manufactures and commercializes novel biosurgical products for applications in Reconstructive Medicine and Tissue Engineering. ColBar’s products are based on the company’s proprietary programmed biomatrices (PBMs). PBMs are collagen-based matrices with a programmed biodurability (functional longevity) and long-term shape preservation.

TECHNOLOGY

ColBar LifeScience Ltd. (ColBar) has developed a proprietary collagen cross-linking technology, which is based on the non-enzymatic glycation process that naturally occurs in the body. This GlymatrixT cross linking technology, the culmination of years of research into glycation as a cross linking mechanism, utilizes a natural, sugar-based, cross-linking agent (d-ribose), much like it is done in the human body.

When injected into the tissue in its molecular or fibrillar state, collagen degrades quickly. For its ‘in situ’ life to be extended collagen must be cross-linked. To date, a variety of chemical and physical techniques have been employed to control the properties of collagen-based products for reconstructive and aesthetic medicine. Yet, such collagen-based products have often had limited success, mainly due to insufficient control over the biodurability and shape of these products in vivo.

The Glymatrix™ technology represents a breakthrough in the design of collagen-based bio-matrices through its ability to specifically engineer biomaterial products with long-lasting effects, enhanced stability and properties similar to those of natural collagen found in the body. It is ideally suited to reconstructive and aesthetic medicine because it enables biological materials to be programmed to perform in a manner appropriate to their intended application.

The sophisticated Glymatrix™ production process is very versatile. In the first stage highly purified type I porcine collagen is manufactured. In the second one the bulk matrix is produced, utilizing the Glymatrix™ cross linking technology. In the third and final stage the bulk matrix is tailored to the specific product application.

The Glymatrix™ technology uniqueness lies in its versatility and ability to control a multitude of important collagen matrix properties, including physico-chemical properties and biological properties. Several preclinical and clinical trials have confirmed the unique nature of this technology, which stems from its ability to accurately imitate processes that occur within the body. Thus, the Glymatrix™ technology enables specific tailoring of collagen matrices for a wide variety of clinical application in many therapeutic areas, like aesthetics, bone & cartilage among others.

Products and Phases

Product	Phase
EVOLENCE	Phase III
ColBar's dermal filler that restores shape to facial wrinkles sets a new standard in biodegradable dermal filler technology.
OSSIX PLUS	FDA Approved
OSSIX Plus is a dental membrane. It is a resorbable porcine-sourced collagen dental membrane for Guided Bone Regeneration (GBR) and Guided Tissue Regeneration (GTR), which is manufactured using ColBar's proprietary GLYMATRIX™ technology.

ESTIMATED ANNUAL SALES

	TARGET MARKETS
	Hospitals, Plastic Surgeons and Cosmetics Companies.

	BUSINESS MODEL
	B2B

REMARKS

Date	Remark
	Company is currently being managed by VAR Management.

CONTACT INFO

Expand / Collapse All

Main Address: Herzliya, Israel

Address	9 Hamenofim St.
POB	12206
City	Herzliya
Country	Israel
Zip	46733

Contact Person	abC Defghij
Company E-mail	abC Defghij
Telephone	abC Defghij
Fax	abC Defghij

Branch Address: Rehovot, Israel

Address	Biotech Industrial Zone
City	Rehovot
Country	Israel

Contact Person	abC Defghij
Company E-mail	abC Defghij
Telephone	abC Defghij
Fax	abC Defghij

	MANAGEMENT

Key Executive

Name	Title	Previous Position
Dr. Matitiahu Nof	Co-Founder
Prof. Sandu Pitaru	Co-Founder
Ms. Rona Steinberg	VP, Aesthetic Business Unit	Dexcel Pharma (Head of Cardiovascular Business Unit)

	BOARD

Board

Member	Title	Affiliation
abC Defghij	Board Member	Former CEO, Agis

Mergers & Acquisitions

Round

Date

Stage

Amount

Valuation

Acquired

Jul. 11, 2006

abCDe

	FINANCIAL ROUNDS

Total Capital Raised
abCDe

Financial Rounds

Numbers of Investors

Expand / Collapse All

Round

Date

Stage

Amount

Valuation

Fifth Round - Extended

Mar. 01, 2006

Initial Revenues

abCDe

Fifth Round

Oct. 01, 2005

Initial Revenues

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Venture Capital Fund	abCDe	Holds 20% of the company
abC Defghij	Venture Capital Fund	abCDe	Holds 6% of the company
abC Defghij	Venture Capital Fund	abCDe	Holds 21% of the company
abC Defghij	Venture Capital Fund	abCDe	Holds 3% of the company
abC Defghij	Investment Company	abCDe	Holds 10% of the company

Venture Lending

Jul. 01, 2005

Initial Revenues

abCDe

Fourth Round

Nov. 30, 2004

Initial Revenues

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Venture Capital Fund	abCDe
abC Defghij	Venture Capital Fund	abCDe
abC Defghij	Venture Capital Fund	abCDe	Holds 5% of the company
abC Defghij	Venture Capital Fund	abCDe
abC Defghij	Venture Capital Fund	abCDe	Led the round
abC Defghij	Investment Company	abCDe

Third Round

Oct. 01, 2003

Initial Revenues

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Venture Capital Fund	abCDe
abC Defghij	Venture Capital Fund	abCDe
abC Defghij	Venture Capital Fund	abCDe
abC Defghij	Investment Company	abCDe

Second Round

Dec. 20, 2000

R&D

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Venture Capital Fund	abCDe
abC Defghij	Venture Capital Fund	abCDe
abC Defghij	Investment Company	abCDe

Internal Round

Mar. 01, 1999

R&D

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Venture Capital Fund	abCDe
abC Defghij	Investment Company	abCDe

Other

Jan. 01, 1999

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Investment Company	abCDe
abC Defghij	Investment Company	abCDe

First Round

May. 01, 1998

R&D

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Venture Capital Fund	abCDe
abC Defghij	Investment Company	abCDe

Last Updated:	abCDe
IVC Number:	abCDe